149690-05-1

149690-05-1 structure

Name: Sacubitril sodium
Chemical Name: sodium,4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate
CAS Number: 149690-05-1
Molecular Formula: C₂₄H₂₈NNaO₅
Molecular Weight: 433.47300
Catalog: Signaling Pathways Metabolic Enzyme/Protease Neprilysin
Create Date: 2017-07-06 00:28:56
Modify Date: 2024-01-08 12:42:34
Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19[1][2][3].

Name	sodium,4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate
Synonyms	AHU-377 sodium salt UNII-MOP72GEP8Z

Description	Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19[1][2][3].
Related Catalog	Research Areas >> Cardiovascular Disease Research Areas >> Infection Signaling Pathways >> Metabolic Enzyme/Protease >> Neprilysin
In Vitro	Sacubitril sodium increases neprylisin-degraded peptides, such as natriuretic peptides (NPs), peptide natriuretic atrial (ANP) and peptide natriuretic brain (BNP)[2].
In Vivo	In normotensive rats, pretreatment with Sacubitril sodium (3, 10 and 30 mg/kg, PO.) augments ANP-evoked plasma cGMP levels by 2.4, 3.3 and 4.0 fold, respectively (4h AUC compared to vehicle)[1]. Sacubitril sodium (30 and 100 mg/kg, PO) produces a dose-dependent antihypertensive effect in Dahl-SS rats[1].
References	[1]. Hegde, L.G., et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. BMC Pharmacol 11, P33 (2011). [2]. Vitiello A, et al. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul 27:bmjebm-2020-111497. [3]. Chrysant SG. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. J Am Soc Hypertens. 2017 Jul;11(7):461-468.

Molecular Formula	C₂₄H₂₈NNaO₅
Molecular Weight	433.47300
Exact Mass	433.18700
PSA	99.02000
LogP	4.54780
Storage condition	2-8°C

Hazard Codes	Xi

Precursor 0
DownStream 1
149709-62-6

149690-05-1	59798-30-0
12676-22-1	91996-54-2
81075-52-7	30605-57-3
61538-65-6	107910-75-8
807636-25-5	71119-23-8